2-氯-N-(1,1-二甲基乙基)-4-氨基嘧啶 | 876521-19-6

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-N-(1,1-二甲基乙基)-4-氨基嘧啶
• 中文别名: 2-氯-n-(1,1-二甲基乙基)-4-嘧啶胺
• 英文名称: N-(tert-butyl)-2-chloropyrimidin-4-amine
• 英文别名: N-tert-butyl-2-chloropyrimidin-4-amine
• CAS: 876521-19-6
• 化学式: C₈H₁₂ClN₃
• 分子量: 185.656
• InChiKey: YWLVEBCUJRKAMO-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C
• 沸点：
  325.3±15.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-tert-Butyl-2-chloropyrimidin-4-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-tert-Butyl-2-chloropyrimidin-4-amine
CAS number: 876521-19-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H12ClN3
Molecular weight: 185.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-N-(1,1-二甲基乙基)-4-氨基嘧啶 、 4-methoxy-3-(3-pyrrolidin-1-ylpropoxy)aniline 在 对甲苯磺酸 作用下， 以 异丙醇 为溶剂， 反应 3.0h， 以18%的产率得到N⁴-(tert-butyl)-N²-(4-methoxy-3-(3-(pyrrolidin-1-yl)propoxy)phenyl)pyrimidine-2,4-diamine hydrochloride
  参考文献：
  名称：

  [EN] AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS
  [FR] COMPOSÉS ARYLE OU HÉTÉROARYLE À SUBSTITUTION AMINE UTILISÉS COMME INHIBITEURS DE EHMT1 ET EHMT2

  摘要：

  本公开涉及氨基取代的芳基或杂芳基化合物。本公开还涉及包含这些化合物的药物组合物，以及通过向需要治疗的受试者施用本公开的氨基取代的芳基或杂芳基化合物或其药物组合物，来治疗疾病（例如，镰状细胞性贫血）的方法，该方法通过抑制从EHMT1和EHMT2选择的甲基转移酶酶。本公开还涉及将此类化合物用于研究或其他非治疗目的。

  公开号：

  WO2017181177A1
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 叔丁胺 在 乙酸乙酯 、 二氯甲烷 作用下， 反应 3.0h， 以to afford 2.5 g (63% yield) of the title compound的产率得到2-氯-N-(1,1-二甲基乙基)-4-氨基嘧啶
  参考文献：
  名称：

  QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

  摘要：

  本发明涉及一种在细胞增殖紊乱和癌症治疗中有用的突变异柠檬酸脱氢酶（mt-IDH）蛋白的新型活性抑制剂，其化学式为：其中A、B、W1、W2、W3和R1-R6如本文所述。

  公开号：

  US20160083365A1

文献信息

• Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
  申请人：Deng Xiaohu

  公开号：US20070027319A1

  公开（公告）日：2007-02-01

  This invention relates to methods of making pyrimidinyl-substituted imidazole compounds by sequential substitution of the 4- and 2-chloro groups of 2,4-dichloropyrimidine, nucleophilic substitution to form pyrimidinylalkyne derivatives, oxidation to the corresponding 1,2-diketones, and cyclocondensation reactions.

  这项发明涉及通过对2,4-二氯嘧啶的4-和2-氯基进行顺序取代，亲核取代形成嘧啶基炔衍生物，氧化成对应的1,2-二酮，以及环缩合反应制备嘧啶基取代咪唑化合物的方法。
• Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
  申请人：FORMA TM2, Inc.

  公开号：US10280150B2

  公开（公告）日：2019-05-07

  The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.

  本发明涉及具有新变态活性的突变型异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，可用于治疗细胞增殖障碍和癌症，其分子式如下： 其中A、B、W1、W2、W3和R1-R6如本文所述。
• An Efficient Route to 4-Aryl-5-pyrimidinylimidazoles via Sequential Functionalization of 2,4-Dichloropyrimidine
  作者：Xiaohu Deng、Neelakandha S. Mani

  DOI：10.1021/ol052663x

  日期：2006.1.1

  Starting from 2,4-dichloropyrimidine, a concise synthetic route to medicinally important 4-aryl-5-pyrimidinylimidazoles is described. Sequential substitution of the 4- and 2-chloro groups using a regioselective Sonogashira coupling, followed by nucleophilic substitution, led to pyrimidinylalkyne derivatives, which were then oxidized to their corresponding 1,2-diketones. These 1,2-diketones, on cyclocondensation with ammonium acetate and an aldehyde, furnished the desired pyrimidinyl imidazoles in good overall yields.
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP3442947A1

  公开（公告）日：2019-02-20
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20170355712A1

  公开（公告）日：2017-12-14

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.